Brandi T. Johnson

Maximal Adjuvant Activity of Nasally Delivered IL-1α Requires Adjuvant-Responsive CD11c+ Cells and Does Not Correlate with Adjuvant-Induced In Vivo Cytokine Production

A. DeFranco, H. Staats, M. Gunn, 2012, The Journal of Immunology.

Adjuvant-Induced In Vivo Cytokine Production Cells and Does Not Correlate with + Requires Adjuvant-Responsive CD11c α IL-1 Maximal Adjuvant Activity of Nasally Delivered

H. Staats, M. Gunn, L. Thompson, 2012 .

In Vivo Cytokine Production Does Not Correlate with Adjuvant-Induced Cells and + Adjuvant-Responsive CD11c Requires a Delivered IL-1 Maximal Adjuvant Activity of Nasally

A. DeFranco, H. Staats, M. Gunn, 2012 .

A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen.

H. Staats, M. Gunn, S. Abraham, 2013, Vaccine.

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

J. Mascola, R. Baric, E. Boritz, 2021, Science.

Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection.

Michael I. Jordan, Jasmine A. Berry, Mollie R. Cummins, 2023, JAMA.